Trican Biotechnology Co., Ltd.

Allgenesis Biotherapeutics Inc.

Ap Biosciences Inc.

Jiun-Shyang Leou

Huang-Tsu Chen

Li-Tsen Lin

Chung-Yuan Hsu

Yun-Ting Wang

Cheng-Ke Li

Jeng-Horng Her

Ching-Hsuan Hsu

Pei-Tzu Wu

Kevin Zen

Shiou-Ting Chen

Chen-Wei Chiang

The present invention provides a bi-functional fusion protein, (AT)a-Fc-(VT)b, simultaneously targeting vascular endothelial growth factor (VEGF) and angiopoietins (ANGs), wherein AT is an ANG binding motif; and VT is a VEGF binding motif, Fragment crystallizable region (Fc) is an N-terminal of Immunoglobulin G (IgG); each of a and b is an integer from 1 to 10. The bi-functional fusion proteins contain two or more domains of human proteins and are of all human sequences, and thus are expected to be non-immunogenic, and potentially can be used therapeutically in human targeting angiogenesis-associated diseases.

Anti-angiogenesis fusion protein and uses thereof

The present invention provides antibodies that bind to CD47 with high affinity and specificity, and their use in treatment of a cancer.

Human anti-CD47 antibodies and uses thereof

Fusion proteins containing a PDGF binding portion, a VEGF binding portion, and an Fc antibody region are described. Also described are nucleic acids encoding the fusion proteins, compositions comprising the fusion proteins, and methods of using the fusion proteins for treating or preventing clinical conditions characterized by abnormal angiogenesis, such as vascular permeability, edema or inflammation.

Fusion protein comprising a ligand binding domain of VEGF and PDGF

Growing community of inventors

Hsinchu, Taiwan

Jiun-Shyang Leou